 |
인쇄하기
취소
|
Chong Kun Dang’s antihypertensive Dilatrend sales top 66 billion won
Pfizer’s Norvask (amlodipine mesilate) has boasted the highest annual revenue in Korea’s competitive hypertensive market for the past years. But last year, the company’s flagship product is being challenged by Chong Kun Dang Pharmaceutical’s Dilatrend (carvedilol).
Chong Kun Dang said the accumulated sales of Dilatrend topped 66 billion won as of November 30 last year.
The market’s seco...
Chong Kun Dang said the accumulated sales of Dilatrend topped 66 billion won as of November 30 last year.
The market’s seco...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.